University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 33 of 35
Biomarkers of Insomnia and Fatigue in HIV/AIDS (Symptoms and Genetics Study)
NCT00503633
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
NCT00295945
Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine
NCT00256347
Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study
NCT00706459
Acupuncture and Post-Surgical Wound Healing
NCT00260494
Naltrexone Effects on Alcohol Intake
NCT00254670
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
NCT00617539
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
NCT00293371
Effects of Secondhand Smoke on Flight Attendant Health
NCT01639235
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides
NCT00187733
Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison
NCT00344591
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
NCT00301834
Activated Protein C to Treat Acute Lung Injuries
NCT00112164
Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer
NCT00379119
Sleep Disruption in New Mothers: An Intervention Trial
NCT01321710
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00295867
Treatment of Latent TB Infection for Jailed Persons
NCT00128206
Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection
NCT00187759
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
NCT00985907
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
NCT00301951
Role of Positive Affect in Adjustment to HIV
NCT00582023
A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography
NCT00505297
Expert System and Family Assisted Interventions for Chinese Smokers
NCT00714467
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
NCT00305825
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
NCT00187486
The Effect of Rituximab on the Development of Anti-Donor Antibodies
NCT00695097
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
NCT00244374
Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus
NCT00187564
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies
NCT00513318
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms
NCT00243893
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
NCT00303992
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
NCT00309894
Radiation Therapy in Treating Women With Invasive Breast Cancer
NCT00301041
Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)
NCT00643903
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
NCT00126633
Evaluating a Pediatric Asthma Management Education Program for Physicians
NCT00399984
Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia
NCT00312962
A Case Management Intervention to Prevent ER Visits in HIV-infected Persons
NCT00187590
Phosphate Intake's Effect on the Skeletal System - Pilot
NCT00187629
Levetiracetam for Treatment of Pain Associated With Fibromyalgia
NCT00254657
Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)
NCT00187668
Mechanism of Insulin-Resistant in Lean Non-Diabetics
NCT00970099
Safety and Tolerability of Rituximab in Neuromyelitis Optica
NCT00501748
Enhancing Collaboration Between Doctors and Patients to Improve Asthma
NCT00201188
Once Weekly Parathyroid Hormone for Osteoporosis
NCT00065637
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
NCT00274755
Kidney and Liver Transplantation in People With HIV
NCT00074386
Intensive Glycemic Control and Skeletal Health Study
NCT00324350
Tele-Electrocardiography in Emergency Cardiac Care
NCT00075088
Symptom Management After Breast Cancer Surgery
NCT00686127
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.